Key result
Risk-stratified screening with pitavastatin every 24 months is cost-effective at ~$8,300 per QALY gained.
Why the study?
Is risk-stratified cardiovascular screening and tailored statin-based lipid-lowering therapy with electronic pillbox adherence support cost-effective for primary prevention of cardiovascular disease in people with HIV in China?
Is risk-stratified cardiovascular screening and tailored statin-based lipid-lowering therapy with electronic pillbox adherence support cost-effective for primary prevention of cardiovascular disease in people with HIV in China?
Answers are grounded in this paper and cite their sources.
Risk-stratified CVD screening with pitavastatin is cost-effective for people with HIV in China at 1× GDP per capita, while adding ezetimibe and electronic pillbox adherence support becomes optimal at 3× GDP per capita.
Objectives Cardiovascular disease (CVD) is the leading non-AIDS cause of death among people with HIV (PWH). Although statins reduce CVD risk by over one-third, poor adherence limits real-world effectiveness. Electronic pillboxes may bridge this gap, but their cost-effectiveness for CVD primary prevention in PWH remains unclear. Methods We developed a Markov cohort model simulating 100,000 Chinese PWH (aged 40–75 years) over a lifetime horizon from a healthcare system perspective. Strategies varied by CVD screening frequency (every 6/12/24 months), lipid-lowering regimens (pitavastatin alone, or combined with ezetimibe or PCSK9 inhibitor), and electronic pillbox adherence support for high-risk individuals. Incremental cost-effectiveness ratios (ICERs) were calculated as cost per quality-adjusted life-year (QALY) gained versus status quo at willingness-to-pay thresholds of 1 × and 3 × GDP per capita ($13,445 and $40,335) in China. Results Risk-stratified screening every 24 months with pitavastatin alone (without pillboxes) was optimal at 1×GDP per capita (ICER $8,269/QALY), averting 4,298 major adverse cardiovascular events (MACE) and gaining 28,570 QALYs versus status quo. At 3×GDP per capita, 6-monthly screening with risk-tailored therapy (pitavastatin ± ezetimibe) plus electronic pillboxes was optimal (ICER $16,799/QALY), averting 10,169 MACE and gaining 59,125 QALYs. Statin adherence and ezetimibe cost were key drivers of cost-effectiveness. Conclusions Risk-stratified CVD prevention integrating periodic screening and tailored pharmacotherapy is cost-effective for PWH in China. Electronic pillboxes become cost-effective when greater healthcare investment is available, supporting a threshold-dependent approach to translating statin efficacy into population-level impact.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied Cardiovascular disease primary prevention in people with HIV (n=100,000). Risk-stratified CVD screening and tailored lipid-lowering therapy (pitavastatin alone or combined with ezetimibe or PCSK9 inhibitor) with or without electronic pillboxes vs. Status quo (24-month screening interval with ~11% annual screening/statin uptake among medium/high-risk individuals, 50% baseline statin adherence, and no treatment intensification) was evaluated on Incremental cost-effectiveness ratio (ICER, cost per QALY gained) and net monetary benefit (ICER $8,269/QALY for PP-24 at 1x GDP; ICER $16,799/QALY for E-PE-6 at 3x GDP). Risk-stratified screening every 24 months with pitavastatin was optimal at 1x GDP per capita (ICER $8,269/QALY), while 6-monthly screening with pitavastatin±ezetimibe and electronic pillboxes was optimal at 3x GDP (ICER $16,799/QALY).
Synapse has enriched 10 related papers. Consider them for comparative context: